Article Text

Download PDFPDF

1040-C A novel subset of granulocytic MDSCs expressing PD-1 as immunosuppressive regulators and therapeutic targets in gastric cancer
  1. Kazunori Kato1,2,
  2. Takumi Iwasawa1,
  3. Suguru Yamauchi2,
  4. Tetsu Fukunaga2 and
  5. Hajime Orita2
  1. 1Toyo University, Kita-ku, Tokyo, Japan
  2. 2Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background The development and progression of cancers are frequently promoted by immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) mediated by various immune checkpoint molecules. Recently, the immune checkpoint inhibitor anti-PD-1 neutralizing antibody has become available for the first-line treatment of gastric cancer (GC) in Japan. However, there is no correlation between PD-1 or PD-L1 expression in Tregs or GC tissues and clinical responses to anti-PD-1 antibody. MDSCs are immature myeloid cells thought to suppress immune cell action, but the functional cell surface markers that define MDSCs correlated with cancer progression have not yet been clarified well. In this study, we identified a new subset of potential diagnostic and therapeutic targets for MDSCs in GC patients.

Methods A total of 71 patients with GC who visited Juntendo University Hospital were included in the study. The study protocol was approved by the ethical committee of Juntendo University and written informed consent was obtained from all participants prior to enrolment. Flow cytometry was performed on fresh peripheral blood, using flow cytometer/cell sorter. For identification of circulating MDSCs, various fluorochrome-labeled antibodies to CD11b, CD14, CD33, HLA-DR, CD66b, PD-1 and PD-L1, and for T cell activation, antibodies to CD3, CD28, CD69, CD134 and CD137 were used.

Results A significantly higher number of circulating monocytic-MDSCs and granulocytic-MDSCs (G-MDSCs) with CCR2 was detected in advanced GC patients (n=29, Stage III and IV) compared to early stage of GC donors (n=42, Stage I and II). We also found that significantly higher levels of PD-1 and PD-L1 were expressed on G-MDSCs (Lin-/HLA-DR-/CD33+/CD66b++) from advanced than early-stage of GC patients. With the intent to identify the immunosuppressive function of PD-1 on G-MDSCs, isolated G-MDSCs pretreated with anti-PD-1 were mixed with CD3/CD28-activated T cells in vitro. Interestingly, both CD4 and CD8 T cell responses were ameliorated only in the pretreatment of G-MDSCs but not to T cells. We also found that immunosuppressive potential of G-MDSCs in GC patients was attenuated 3 weeks after anti-PD-1 Ab therapy.

Conclusions The result of this pilot study, limited by the patient number, shows a clear increase in peripheral G-MDSCs expressing functional PD-1 in advanced GC patients. Although needed to be confirmed in the relationship between PD-1 on G-MDSCs and the duration of time of anti-PD-1 Ab therapy, these data suggest a novel subset of G-MDSCs expressing PD-1 found in advanced GC could be diagnostic and therapeutic targets.

Ethics Approval Patients with gastric cancer who visited Juntendo University Hospital (Tokyo, Japan) were included in the study. The study protocol was approved by the ethical committee of Juntendo University and written informed consent was obtained from all participants prior to enrolment.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.